“Neoadjuvant and periop chemoimmunotherapy regimens have improved outcomes in resectable NSCLC. This setting offers an excellent platform for testing novel agents and biomarkers. Many studies led by the speaker, Dr. Tina Cascone.”
More posts featuring Chul Kim on oncodaily.com
Dr. Chul Kim holds the position of Associate Professor at Georgetown University, specializing in thoracic oncology. Dr. Kim was recognized with the Norman Rales Young Investigator Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) in 2018.
In 2021, he was presented with the John F. Potter, MD, Award by Georgetown Lombardi Comprehensive Cancer Center. Dr. Kim actively contributes to the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. He has authored more than 60 articles in reputable peer-reviewed journals.
